Genetic and environmental causes of hemorrhagic stroke
Official title: Genetic and Environmental Risk Factors for Hemorrhagic Stroke
Run by State University of New York at Buffalo · NCT00682695 · Data updated 2026-11-12
We will test whether specific genetic variants and environmental factors are linked to the risk of intracerebral hemorrhage in adults.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 1000 (estimated) |
| Sponsor | State University of New York at Buffalo Academic / other |
| Locations | 7 sites (Chicago, Illinois and 6 other locations) |
| Status | Recruiting |
| Started | January 1, 2025 |
| Main results expected | December 31, 2029 |
| Study ends | December 31, 2029 |
| Registry record updated | July 2, 2026 |
| Trial ID | NCT00682695 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults (18+) who are residents at the recruitment center for at least six months and either have had a spontaneous non-traumatic intracerebral hemorrhage or are enrolled as control participants willing to provide blood and clinical information.
✕Probably not a fit
People with hemorrhages caused by trauma, brain tumor/metastases, or infection, those unable to consent, or people seeking direct therapeutic benefit are unlikely to benefit from this observational genetic study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study will perform deep DNA sequencing and gene expression analysis focused on the 1q22 genomic region to find genetic contributors to non-lobar intracerebral hemorrhage (ICH). The team will recruit about 500 non-lobar ICH cases (approximately 150 Black and 350 White) and 1,000 controls to correlate sequence variation with expression levels in the same samples. Findings will be replicated in larger datasets including thousands of additional ICH cases and CHARGE consortium participants with MRI white matter hyperintensity measurements. The work aims to link replicated GWAS signals to functional changes that may explain ICH risk and broader small vessel disease mechanisms.
Why it matters
Potential benefit: If successful, the results could identify people at higher genetic risk for ICH and point to new targets for prevention or therapy.
How similar studies have gone: Previous GWAS work identified a replicated association at 1q22 that this study builds on, but deep sequencing and linked expression analyses at this locus remain less tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18 or older * Resident (6 months or longer) within the recruitment center * Fulfillment of the criteria for spontaneous ICH * No evidence of trauma, brain tumor/metastases or infectious processes as a cause of the hemorrhage * Ability of the patient or legal representative to provide consent for an interview, blood pressure determinations and DNA sampling Exclusion Criteria: * N/A
Where it's running
-
Baptist Health Louisville
Louisville, Kentucky, United States Recruiting -
University of Maryland
Baltimore, Maryland, United States Recruiting -
Massachusetts General Hospital
Boston, Massachusetts, United States Recruiting -
Duke University
Durham, North Carolina, United States Recruiting -
University of Cincinnati
Cincinnati, Ohio, United States Recruiting -
University of Illinois Chicago
Chicago, Illinois, United States Not yet recruiting
Show 1 more location
-
Columbia University
New York, New York, United States Not yet recruiting
Study contacts
- Principal investigator: Daniel Woo, MD — University of Cincinnati
- Study coordinator: Lee A Gilkerson, RN, BSN
- Email: Lee.gilkerson@uc.edu
- Phone: 513-558-6140
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Deep phenotyping to explore recovery in young adults after stroke
This project will test whether a detailed health and sample-collection approach (deep phenotyping) is practical and acceptable for people aged 18–55 who have had a stroke.
-
Stem cell therapy for chronic stroke recovery
This study is testing whether using a patient's own stem cells can help people with long-term stroke recovery feel better and improve their daily functioning.
-
AI-based tools to help diagnose, treat and predict stroke outcomes across multiple hospitals
This study tests AI-powered tools on real-world stroke patients to see if they can improve pre-hospital triage, diagnosis, and outcome prediction while data stay securely within each hospital.
-
Web-based therapy using action observation and mirror therapy for arm weakness after stroke
This trial tests whether a mobile telerehabilitation app delivering action observation therapy (AOT) alone or combined AOT with mirror therapy (AOT-MT) can improve upper limb function in people with subacute stroke.
-
Remote Ischaemic Conditioning for Fatigue After Stroke 2
Aat least 12 weeks after stroke, adults with post-stroke fatigue will try a simple hand-arm cuff treatment at home to see if it helps reduce fatigue.
-
Dual-task balance training plus computer-based cognitive training after stroke
In adults who recently had a stroke, the study tests whether adding computerized cognitive exercises to balance training improves balance and other recovery outcomes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.